COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter studyUniv Pisa, Italy.
Johns Hopkins Univ Hosp, MD 21287 USA.
Univ Penn, PA 19104 USA.
Univ Naples Federico II, Italy.
SYNLAB Suisse SA, Switzerland.
Lab Pathol CSD, Ukraine.
Univ Naples Federico II, Italy.
Univ Hosp Basel, Switzerland.
Univ Hosp Cologne, Germany.
Univ Porto, Portugal.
Linköping University, Department of Biomedical and Clinical Sciences, Division of Neurobiology. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Diagnostics, Clinical pathology.
European Inst Oncol IRCCS, Italy.
Nicolae Testemitanu State Univ Med & Pharm, Moldova.
Univ Paris, France.
A Perrino Hosp, Italy.
Johns Hopkins Univ Hosp, MD 21287 USA.
Univ Porto, Portugal.
Univ Hosp Cologne, Germany.
G Martino Hosp, Italy.
Univ Pisa, Italy.
Locarno Cantonal Hosp, Switzerland.
Pasteur Hosp, France.
Univ Naples Federico II, Italy.
G Martino Hosp, Italy.
Duke Univ, NC 27710 USA.
Izumi City Gen Hosp, Japan.
Univ Clin Golnik, Slovenia.
Tampere Univ, Finland.
Queen Alexandra Hosp, England.
Univ Texas MD Anderson Canc Ctr, TX 77030 USA.
Kapoor Path Labs, India.
Univ Clin Navarra, Spain.
Univ Naples Federico II, Italy.
Johns Hopkins Univ Hosp, MD 21287 USA.
Univ Witwatersrand, South Africa.
Johns Hopkins Univ Hosp, MD 21287 USA.
Baku Pathol Ctr, Azerbaijan.
Baskent Univ, Turkey.
Tekirdag Namik Kemal Univ, Turkey.
Gen Univ Hosp Alicante, Spain.
Queen Alexandra Hosp, England.
Ctr Diagnost Pathol, Poland.
Duke Univ, NC 27710 USA.
Univ Cattolica Sacro Cuore, Italy.
Univ Texas MD Anderson Canc Ctr, TX 77030 USA.
Santa Casa Med Sch, Brazil.
Univ Hosp Basel, Switzerland.
Univ Porto, Portugal.
Gen Univ Hosp Alicante, Spain.
Univ Hosp Dubrava, Croatia.
Lab Pathol CSD, Ukraine.
Harvard Med Sch, MA 02115 USA.
G Martino Hosp, Italy.
Erasmus MC, Netherlands.
Harvard Med Sch, MA 02115 USA.
Amer Hosp Paris, France.
Imperial Coll Healthcare, England.
Pathol Anat Natl Automated Arch PALGA Fdn, Netherlands.
Univ Hosp Leuven, Belgium.
Univ Salerno, Italy.
Harvard Med Sch, MA 02115 USA.
Harvard Med Sch, MA 02115 USA.
Univ Naples Federico II, Italy.
Show others and affiliations
2022 (English)In: Cancer Cytopathology, ISSN 1934-662X, E-ISSN 1934-6638, Vol. 130, no 5, p. 344-351Article in journal (Refereed) Published
Abstract [en]
Background In a previous worldwide survey, the authors showed a drastic reduction in the number of cytological specimens processed during the coronavirus disease 2019 "lockdown" period along with an increase in malignancy rates. To assess the continued impact of the pandemic on cytological practices around the world, they undertook a second follow-up worldwide survey collecting data from the post-lockdown period (2020). Methods Participants were asked to provide data regarding their cytopathology activity during the first 12 weeks of their respective national post-lockdown period (2020), which ranged from April 4 to October 31. Differences between the post-lockdown period and the corresponding 2019 period were evaluated, and the authors specifically focused on rates of malignant diagnoses. Results A total of 29 respondents from 17 countries worldwide joined the survey. Overall, a lower number of cytological specimens (n = 236,352) were processed in comparison with the same period in 2019 (n = 321,466) for a relative reduction of 26.5%. The overall malignancy rate showed a statistically significant increase (12,442 [5.26%] vs 12,882 [4.01%]; P < .001) during the same time period. Similar results were obtained if both malignancy and suspicious for malignancy rates were considered together (15,759 [6.58%] vs 16,011 [4.98%]; P < .001). Conclusions The data showed a persistent reduction in the cytological specimen volume during the post-lockdown period (2020). However, the relative increase in the cytological workload in the late part of the post-lockdown is a promising finding of a slow return to normality.
Place, publisher, year, edition, pages
WILEY , 2022. Vol. 130, no 5, p. 344-351
Keywords [en]
cancer screening program; coronavirus disease 2019 (COVID-19); cytopathology; fine-needle aspiration; malignancy rate
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-182342DOI: 10.1002/cncy.22547ISI: 000740748200001PubMedID: 35006650Scopus ID: 2-s2.0-85122709300OAI: oai:DiVA.org:liu-182342DiVA, id: diva2:1629632
Note
Funding Agencies|Monitoraggio ambientale, studio ed approfondimento della salute della popolazione residentein aree a rischio-In attuazione della D.G.R. Campania [180/2019]; POR Campania FESR 2014--2020 Progetto "Sviluppo di Approcci Terapeutici Innovativi per patologie Neoplastiche resistenti ai trattamenti (SATIN)"; Campania Region for the Investigation of the Molecular Biology of Thyroid Cancer [24 29/12/2005]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 CA016672]
2022-01-182022-01-182023-03-21